close

Clinical Trials

Date: 2011-09-07

Type of information: Results

phase:

Announcement: results

Company: Verona Pharma (UK)

Product: VRP700

Action mechanism:

VRP700’s mechanism of action involves the suppression of cough initiating signals originating at cough sensory nerve endings located in the lungs.

Disease:

chronic intractable cough due to underlying lung disease

Therapeutic area: Respiratory diseases - Lung diseases

Country: Italy

Trial details:

The trial was a double-blind, cross-over, placebo-controlled, contingency study to assess the anti-tussive effects of VRP700 in patients with chronic intractable cough. Each patient received two treatments, either VRP700 or placebo inhaled from a nebuliser device.

Latest news:

Verona Pharma has announced the results of the clinical trial of its novel cough drug, VRP700, conducted at the University of Florence, Italy. By all the measures used, VRP700 significantly reduced coughing in patients with chronic intractable cough due to underlying lung disease. This beneficial effect was not associated with any adverse effects. The study met all of its primary and secondary endpoints. The primary endpoint was the number of coughs recorded, with VRP700 producing a significant reduction in the number of coughs (p values 0.01 to 0.001) compared to both placebo and pre-treatment values.
A secondary endpoint was the attending physicians’ blind assessment of the patients’ coughing, with the post-treatment period being clinically superior to the pre-treatment period at a statistical significance of pAnother secondary endpoint was the patients’ subjective blind assessment of treatment, with a statistically significant number of patients (p<0.01) reporting that they felt improved comfort during drug treatment.
Patients were also asked to identify in which of the two treatment periods they received the drug, with the VRP700 treatment period being correctly identified in almost 90% of cases. The data from the trial will be used to further advance the clinical value of VRP700, including identifying and developing a second generation of compounds as well as further clinical studies to facilitate the introduction of VRP700 as a novel, first in class inhaled medicine for the treatment of cough.

Is general: Yes